AS101

Phase 2Small molecule

BBioMAS Ltd

AS101 is one of 168 small molecule programs targeting Thrombocytopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

Androgenetic AlopeciaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

ThrombocytopeniaPhase 2

Active, not recruiting

Androgenetic AlopeciaPhase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Taltz

Eli Lilly

Preclinical

20 4

AS101

BBioMAS Ltd

Phase 2

1 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Raptiva

Roche

Preclinical

10 8

Siliq

BBausch Health Americas, Inc.

Preclinical

14 9

Victoza

Novo Nordisk

Preclinical

2 10

Lovenox

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients

Suspended·BBioMAS Ltd·Phase 2·NCT01010373·12 enrolled

Androgenetic Alopecia1 trial

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Unknown status·RRabin Medical Center·Phase 2·NCT00418249·40 enrolled

Thrombocytopenia1 trial

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Terminated·BBioMAS Ltd·Phase 2·NCT00926354·40 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Completed·BBioMAS Ltd·Phase 1/2·NCT01555112·12 enrolled

Psoriasis1 trial

Topical Application of AS101 for the Treatment of Psoriasis

Withdrawn·BBioMAS Ltd·Phase 2·NCT00788424

1 more indication

Atopic Dermatitis1 trial

Topical Application of AS101 for the Treatment of Atopic Dermatitis

Terminated·BBioMAS Ltd·Phase 2·NCT00927212·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for AS101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AS101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AS101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioMAS Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioMAS Ltd

AS101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Androgenetic Alopecia1 trial

Thrombocytopenia1 trial

Safety and Efficacy1 trial

Psoriasis1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News